Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Cantor Fitzgerald handhaafde dinsdag zijn neutrale standpunt voor aandelen Pfizer Inc. (NYSE: PFE) met een koersdoel van $ 24 ...

Citi-analisten hebben maandag hun Neutraal advies voor het Pfizer-aandeel (NYSE: PFE) herhaald, met een koersdoel van $ 25,00 ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Via een deal van potentieel 6 miljard dollar neemt het Amerikaanse Pfizer een licentie op een experimenteel kankermedicijn van het Chinese 3SBio. Het illustreert de appetijt van de westerse ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...